Fennec Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals

~ achieved pedmark® full-year 2023 net product sales of $21.3 million, including $9.7 million in net product sales in the fourth quarter of 2023 ~

Research triangle park, n.c., march 19, 2024 (globe newswire) -- fennec pharmaceuticals inc. (nasdaq: fenc; tsx: frx), a commercial stage specialty pharmaceutical company, today announced that the company will release its full year and fourth quarter 2023 financial results before the opening of the u.s. financial markets on thursday, march 21, 2024. management will host a conference call and webcast that day to discuss the company's financial and business results.

Agreement pairs norgine's commercial expertise and leading european footprint with pedmarqsi® , the first and only approved therapy in the european union and u.k. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors

~ fourth quarter 2023 net revenues of approximately $9.2 to $9.7 million ~ ~ company expects to report 2023 fourth quarter and audited full-year results on or about march 26, 2024 ~ research triangle park, n.c., feb. 29, 2024 (globe newswire) -- fennec pharmaceuticals inc. (nasdaq: fenc; tsx: frx), a commercial stage specialty pharmaceutical company, today announced preliminary unaudited fourth quarter and full-year 2023 net revenues.

Research triangle park, n.c., feb. 01, 2024 (globe newswire) -- fennec pharmaceuticals inc. (nasdaq: fenc; tsx: frx), a commercial stage specialty pharmaceutical company, today announced that the u.s. food and drug administration (fda) has issued a public reminder to healthcare providers that pedmark (sodium thiosulfate injection) is not substitutable with other sodium thiosulfate products as explicitly directed in its prescribing label. pedmark is the first and only fda approved therapy indicated to reduce the risk of ototoxicity (e.g., permanent hearing loss) associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.

Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.26 per share a year ago.

Fennec (FENC) signs a licensing deal with Nordine, granting the latter rights to Pedmarqsi in the EU, Australia and New Zealand to treat cisplatin-induced hearing loss. The stock rises 11.4%.

Adherex Technologies Inc. (FENC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, March 21, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results.

The consensus price target hints at a 64.6% upside potential for Adherex Technologies Inc. (FENC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Fennec released sales guidance for Q4 2023, exceeded analyst expectations. A pending EU launch of PEDMARK® provides a near term opportunity for the Company to finalize an EU partnership. Revenue growth in the US, and completion of a Japanese bridging study provide opportunities for further geographic partnerships, or a sale of the Company.

Adherex Technologies Inc. (FENC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

The mean of analysts' price targets for Adherex Technologies Inc. (FENC) points to an 81% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor meetings at the conferences.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q3 2023 Earnings Conference Call November 6, 2023 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Rosty Raykov - Chief Executive Officer Adrian Haigh - Chief Operating Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Naureen Quibria - Capital One Securities Charles Duncan - Cantor Fitzgerald Dipesh Patel - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Third Quarter 2023 Earnings and Corporate Update Conference Call.